ST. LOUIS, Missouri, January 05, 2016 – Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for use in treating certain cancers, pain, and inflammation, today announced that Bobby W. Sandage, Jr., Ph.D., Euclises’ Chief Executive Officer, will present at the 8th Annual Biotech Showcase 2016 conference on January 13, 2016 at 3:00 PM Pacific Time. Dr. Sandage will provide an overview of Euclises’ business and of the company’s lead oncology candidate, ECP-1014. The conference will be held at the Parc 55 Hotel in San Francisco, CA.


About Euclises Pharmaceuticals, Inc.

Euclises Pharmaceuticals, Inc. is a biopharmaceutical company advancing novel cyclooxygenase- 2 (COX-2) inhibitors (Euclicoxibs TM) for use in the treatment of cancer. Working with development partner Guangzhou Institutes of Biomedicine and Health (GIBH), Euclises has selected a clinical development candidate (ECP-1014) and is currently conducting IND-enabling studies in preparation for human clinical trials. The company is headquartered within the BioGenerator Labs at CORTEX and supported by funding from Cultivation Capital, BioGenerator, Missouri Technology Corporation, the St. Louis Arch Angels, and other investors. For more information, visit the Euclises website at

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations, estimates, forecasts, and projections as well as the current beliefs and assumptions of the Company’s management. Words such as “outlook,” “believes,” “expects,” “appears,” “may,” “will,” “should,” “anticipates,” or the negative thereof or comparable terminology, are intended to identify such forward-looking statements. Any statement that is not a historical fact is a forward-looking statement. Forwardlooking statements are only predictions and are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore actual results may differ materially and adversely from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update the information contained in this press release.

George Capps
Euclises Pharmaceuticals, Inc.
(314) 932-4032 x317